Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NovoCure Ltd (NVCR)

NovoCure: Director Timothy Scannell retires from board effective September 2, 2026

Neutral Impact 2 of 5 leadership Written later

NovoCure director Timothy Scannell has retired from the board, and his seat was vacated effective September 2, 2026. The filing says the retirement after five years of service did not result from any disagreement with the company or its management.

Key points

  • Timothy Scannell, a director for five years, retired from the board effective September 2, 2026.
  • The filing states the retirement was not due to any disagreement with the company or management.
  • The filing contains no replacement director or new appointment.
  • Form 8-K was filed September 9, 2026, signed by CFO Christoph Brackmann.

The filing

CompanyNovoCure Ltd (NVCR)
Form8-K, current report
Filed with the SECSep 9, 2026, 7:02 AM ET
Accession number0001645113-26-000068

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.